Dr. Jin Yuyan is the head of Clinical and Non-Clinical development at Sanegenebio. She earned her Ph.D. in Clinical Pharmacology from the University of Pittsburgh, served as a critical path fellow for two years at the US FDA, and completed a one-year global clinical scholar program at Harvard Medical School. Before joining Sanegenebio, Dr. Jin worked at Pfizer's US headquarter and Roche China Innovation Center, where she has led or contributed to preclinical research, clinical development, and regulatory submissions for multiple innovative early and late stage programs. Her expertise spans across neuroscience, oncology, infection, and immunology. Dr. Jin has also contributed to multiple technical guidance documents in China as a member of scientific expert committees. She has published numerous scientific papers in internationally renowned journals as the first author or corresponding author, and serves as a reviewer for several internationally recognized journals, such as 《Clinical Pharmacology and Therapeutics》、《Journal of Clinical Pharmacology》、《British Journal of Clinical Pharmacology》.

圣因生物临床与非临床负责人，高级副总裁

金博士于美国匹兹堡大学获得临床药理学博士，在美国药监局担任两年关键路径研究员, 并于哈佛大学医学院完成一年的全球临床学者学习。在加入圣因生物之前，金博士曾先后任职于辉瑞美国总部和罗氏中国创新中心，主导多个创新药物的临床前研究、临床开发、和监管提交，专业知识涵盖神经科学、肿瘤学、感染学和免疫学等多个领域。金博士担任多个中国科学专家委员会成员，在国际知名刊物以第一作者或通讯作者发表多篇科学论文，并担任多个国际知名杂志审评员，例如《Clinical Pharmacology and Therapeutics》、《Journal of Clinical Pharmacology》、《British Journal of Clinical Pharmacology》等。